Free Trial

Green Thumb Industries (OTCMKTS:GTBIF) Shares Down 7.4% - Here's What Happened

Green Thumb Industries logo with Medical background

Key Points

  • Green Thumb Industries Inc. shares fell by 7.4% during trading, closing at $7.61, with a trading volume down 16% from the average.
  • The company reported earnings per share of ($0.01), missing the consensus estimate of $0.04, while revenues for the quarter reached $293.26 million, exceeding analyst estimates.
  • Analysts have mixed ratings on the stock, with an average rating of "Buy" following recent upgrades and downgrades, indicating some confidence in its potential.
  • MarketBeat previews the top five stocks to own by October 1st.

Green Thumb Industries Inc. (OTCMKTS:GTBIF - Get Free Report) shares dropped 7.4% during trading on Monday . The stock traded as low as $7.61 and last traded at $7.61. Approximately 398,060 shares traded hands during mid-day trading, a decline of 16% from the average daily volume of 471,413 shares. The stock had previously closed at $8.22.

Analyst Upgrades and Downgrades

GTBIF has been the topic of several analyst reports. Zacks Research upgraded Green Thumb Industries from a "strong sell" rating to a "hold" rating in a research report on Friday, September 5th. Benchmark restated a "buy" rating on shares of Green Thumb Industries in a research report on Monday, August 11th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of "Buy".

Check Out Our Latest Stock Analysis on GTBIF

Green Thumb Industries Trading Down 7.4%

The company has a market capitalization of $1.58 billion, a price-to-earnings ratio of 69.19 and a beta of 1.22. The firm has a 50-day moving average price of $7.46 and a 200-day moving average price of $6.23.

Green Thumb Industries (OTCMKTS:GTBIF - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.01) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.05). Green Thumb Industries had a net margin of 2.51% and a return on equity of 1.62%. The firm had revenue of $293.26 million for the quarter, compared to analyst estimates of $280.66 million. Equities research analysts predict that Green Thumb Industries Inc. will post 0.32 EPS for the current fiscal year.

About Green Thumb Industries

(Get Free Report)

Green Thumb Industries Inc manufactures, distributes, markets, and sells of cannabis products for medical and adult-use in the United States. It operates through two segments, Retail and Consumer Packaged Goods. The company offers cannabis flower; processed and packaged products, including pre-rolls, concentrates, vapes, capsules, tinctures, edibles, topicals, and other cannabis-related products under the &Shine, Beboe, Dogwalkers, Doctor Solomon's, Good Green, incredibles, and RHYTHM brands.

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Green Thumb Industries Right Now?

Before you consider Green Thumb Industries, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Green Thumb Industries wasn't on the list.

While Green Thumb Industries currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report
Like this article? Share it with a colleague.